INTRODUCTION
============

Developed in the 1950s, monoamine oxidase (MAO) inhibitors were the first effective medications for the treatment of depression, and probably remain some of the most effective agents today despite the introduction of newer drugs ([@bib37]). Unfortunately, the early MAO inhibitors were non-selective and irreversibly inhibited both MAO isoforms (MAO-A and MAO-B) in the gut as well as in the brain, causing serious hypertensive reactions following the ingestion of foodstuffs containing tyramine. This is referred to as the 'cheese effect\' ([@bib13]). The antidepressant effect of MAO inhibitors is generally attributed to their inhibition of brain MAO-A, which breaks down the neurotransmitters serotonin and norepinephrine, are involved with mood, and are targets for most antidepressants ([@bib22]; [@bib12], review).

Selegiline (L-deprenyl) is an irreversible inhibitor of MAO-B with selectivity for MAO-B *vs* MAO-A ([@bib33]; [@bib35]). At low doses (10 mg/day, oral), selegiline specifically inhibits brain MAO-B while leaving brain MAO-A substantially intact ([@bib32]; [@bib15]), and is used to treat Parkinson\'s disease. However, controlled studies have demonstrated antidepressant activity for high doses of oral selegiline, suggesting that when plasma levels of selegiline are elevated, its selectivity for MAO-B is lost resulting in MAO-A inhibition, producing antidepressant activity and requiring the limitation of dietary tyramine ([@bib31]; [@bib36]; [@bib39], [@bib40]; [@bib27]).

To reduce the inhibition of gut MAO-A, two different formulations of selegiline have been developed. Selegiline transdermal system (Emsam) enables absorption from the skin directly into the bloodstream. Preclinical measurements in guinea pigs showed preferential inhibition of CNS MAO-A and MAO-B compared with intestinal and hepatic tissues unlike oral administration, which resulted in similar levels of brain and gut MAO-A inhibition ([@bib28]). Pharmacokinetic studies in healthy humans comparing the selegiline transdermal system with oral selegiline capsules showed a significant reduction in both tyramine pressor sensitivity and amphetamine metabolites ([@bib4], [@bib5]). The use of selegiline transdermal system enabled controlled clinical trials to treat depression without dietary restrictions ([@bib6]; [@bib2]; [@bib11]).

Zydis selegiline (Zelapar) is a freeze-dried formulation, which when allowed dissolving on the tongue without swallowing, is absorbed primarily through the buccal mucosa into the bloodstream thereby reducing the opportunity for first pass metabolism and inhibition of gut MAO. Pharmacokinetic studies have shown that Zydis selegiline inhibits MAO-B at one-eighth of the conventional oral dose (10 mg/day) and decreases amphetamine metabolites by 80--90% ([@bib7], [@bib8]; [@bib25]). In addition, repeated doses of Zydis selegiline 10 mg (but not the 1.25 mg dose) resulted in a significant reduction in the urinary excretion of 5-hydroxy-indoleacetic acid, a peripheral marker for MAO-A activity consistent with inhibition of MAO-A in addition to MAO-B ([@bib7]). However, even though the antidepressant activity of high dose and other formulations of selegiline have been attributed to the inhibition of brain MAO-A ([@bib12] for review), this has never been confirmed in humans.

The purpose of this study was to investigate whether formulations of selegiline, which bypass first-pass metabolism, also inhibit brain MAO-A in humans utilizing positron emission tomography (PET) imaging and the MAO-A radiotracer \[^11^C\]clorgyline ([@bib16]). We examined different daily doses of Zydis selegiline (2.5, 5.0, or 10 mg) given for 28 days to 18 healthy human subjects and by the selegiline transdermal system (6 mg/day) in 3 subjects. As dopamine transporter (DAT) inhibition has also been suggested as a possible mechanism for the antidepressant activity of selegiline ([@bib27]), we also measured DAT availability in three subjects receiving the 10 mg dose of Zydis selegiline using the DAT radiotracer, \[^11^C\]cocaine ([@bib17]).

MATERIALS AND METHODS
=====================

This study was carried out at Brookhaven National Laboratory and approved by the local Institutional Review Board (Committee on Research Involving Human Subjects, Stony Brook University). All subjects gave their written informed consent.

Subjects and Study Design
-------------------------

Twenty-eight subjects were screened and twenty normal healthy non-smoking males aged 18--38 years were enrolled. Inclusion criteria were: healthy, non-smoking males, body mass index (BMI, kg/m^2^) ⩾21 and ⩽30, able to understand and give informed consent. Key exclusion criteria included presence of a significant acute or chronic medical disorder that might complicate or interfere with MAO inhibitor therapy, current or past psychiatric or neurological disease, cardiovascular disease, endocrinological disease, history or presence of phenylketonuria, and history of substance abuse, including alcohol or nicotine abuse as defined by DSM-IV criteria, within the past 12 months. All subjects were instructed to abstain from taking prescription or nonprescription drugs within 7 days (2 months for neuroleptics and fluoxetine or any other drug with a prolonged half-life) and to adhere to a low-tyramine diet during the study and 2 weeks following study participation. Subject demographics are summarized in [Table 1](#tbl1){ref-type="table"}. All study participants also consented to participate in an imaging genetic study and provided blood sample for MAO-A genotyping as described previously ([@bib34]).

This was an open-label, non-randomized, single-center study designed to evaluate the effects of administration of three different daily doses of Zydis selegiline (2.5, 5.0, or 10.0 mg) on healthy subjects for 28 days on brain MAO-A. Six subjects were assigned to each dose. Three subjects were assigned to the Emsam group (6 mg/24 h). One subject participated in both the Zydis selegiline (2.5 mg) and the Emsam groups. Zelapar Orally Disintegrating Tablets, each containing 1.25 mg of selegiline Zydis formulation, were administered orally by dissolution on the tongue (not swallowed). Instructions for dosing and the first dose of Zydis selegiline was observed by study personnel after the baseline PET scan. Subjects were instructed not to take the last tablets on the day before the second PET scan but to wait as it would be administered 2 h before the last PET scan. Each 6 mg/24 h Emsam patch was supplied as a 20 mg/20 cm^2^ transdermal system and the first patch was applied following the baseline PET scan. The duration of treatment was 28 days and the last patch was applied 2 h before the second PET scan.

A treatment log was provided to each subject and weekly phone reminders were made to take the medication and to follow dietary restrictions. Missed doses were noted on the dispensing logs. Subjects who missed 20% of the doses were withdrawn from the study. Subjects were instructed to return unused study drugs and empty wrappers, which were inventoried to assess subject compliance throughout the treatment period.

Zydis selegiline tolerability was assessed as oropharyngeal irritation at baseline and day 28. Blood and urine samples for clinical laboratory tests were obtained at screening, day 28 and the post-treatment follow-up visit. Adverse event queries were conducted at each visit and during periodic telephone calls during dosing. Vital signs were measured at screening, baseline, immediately before and after each PET scan, and at the follow-up visit.

\[^11^C\]Clorgyline and \[^11^C\]Cocaine PET Scans
--------------------------------------------------

\[^11^C\]Clorgyline synthesis and PET scans were carried out as described previously ([@bib26]; [@bib3]). Each subject had two PET scans with \[^11^C\]clorgyline (average 6.6±0.9 mCi/scan; specific activity, 0.9±0.4 mCi/nmol at time of injection), one at baseline and the second at 28 days after dosing. An arterial plasma input function for \[^11^C\]clorgyline was measured ([@bib1]). Three subjects who received the 10 mg Zydis selegiline dose also had a scan with \[^11^C\]cocaine (average 7.2±0.4 mCi/scan; specific activity, 0.95±0.31 mCi/nmol at time of injection) on the same day (2 h apart) using the synthesis and scanning protocol reported previously ([@bib43]).

Image Analysis
--------------

Emission data were attenuation corrected and reconstructed using filtered back projection. Region of interest (ROI) placement for the \[^11^C\]clorgyline and the \[^11^C\]cocaine scans was made as described previously ([@bib14]; [@bib42]). Composite images were created by first normalizing each subject\'s scan to a standard template. Images from each of the six MAO-A subjects or three DAT subjects were then averaged at baseline and post dosing with 10 mg of Zydis selegiline.

Data Analysis
-------------

For quantification of MAO-A activity, PET time-activity data for \[^11^C\]clorgyline from different brain regions and time-activity data in arterial plasma were used to calculate the model terms *K*~1~ and *λk*~3~ at baseline and after Zydis selegiline and Emsam. The model term *K*~1~ is related to blood flow (*F*) and permeability surface area product (PS) *via* the *K*~1~=*F(*1*-e-(*PS*/F)*. The model term *λk*~3~ is a function of the concentration of catalytically active MAO-A molecules, where *k*~3~ is related to the irreversible binding of \[^11^C\]clorgyline by MAO-A, *k*~2~ is related to the efflux of radiotracer from brain to blood and *λ* is defined as *K*~1~*/k*~2~ and is independent of blood flow ([@bib16]; [@bib23]). \[^11^C\]Clorgyline binding (*λk*~*3*~) in human brain has recently been shown to be proportional to MAO-A protein content ([@bib41]). For the \[^11^C\]cocaine scans, PET time-activity curves in the caudate, putamen, and cerebellum and the arterial input function were used to calculate *K*~1~ and the non-displaceable binding potential (BP~ND~) as an index of DAT availability using the Logan plot ([@bib24]).

Estimation of the Degree of Inhibition of \[^11^C\]Clorgyline Binding to MAO-A by Zydis Selegiline and Emsam
------------------------------------------------------------------------------------------------------------

For each subject, a *λk*~3~ value for each of the 12 ROIs was determined at baseline and after Zydis selegiline or Emsam administration. A composite global *λk*~3~ value for each subject at baseline and after drug was also determined by averaging the regional *λk*~3~ values. For each subject, the percent inhibition of MAO-A was determined from the percent change in *λk*~3~ relative to baseline for each of the ROIs and these values were averaged to give an average percent change (mean±SD) at each drug dose.

Statistical Analysis of \[^11^C\]Clorgyline Data and \[^11^C\]Cocaine Data
--------------------------------------------------------------------------

A one-way ANOVA analysis was used to examine whether there was a significant dose-related change in the % inhibition of \[^11^C\]clorgyline binding (*λk*~3~) after a 28-day dosing regimen for the 2.5 *vs* 5.0 *vs* 10.0 mg Zydis selegiline doses. Pair-wise differences were examined *via* the Tukey method at the family-wise error rate of 0.05 (one-tailed) with two-tailed test being used to examine differences in *K*~1~. Unpaired *t*-test was used to examine whether there was a statistically significant difference in the percent change in \[^11^C\]clorgyline binding for the Zydis selegiline 10-mg group and the Emsam group. For the 10-mg group, we subjected the individual ROI data to a repeated measures ANOVA analysis to determine whether the percent change differed between the ROIs. To assess whether subject characteristics (age and BMI) and weight-adjusted dose influenced the percent change in MAO-A, we performed correlation analysis for each dose group. A comparison of BP~ND~ for \[^11^C\]cocaine at baseline and after the 10 mg dose of Zydis selegiline was made using a paired *t*-test, two-tailed. We also performed a correlation analysis between the % change in DAT and the % change in MAO-A for the three subjects in whom both measures were made.

RESULTS
=======

There was no statistical difference in age or BMI for the three dose groups for Zydis selegiline ([Table 1](#tbl1){ref-type="table"}). All doses of Zydis selegiline and the Emsam patch were tolerated and there were no adverse events and no changes in vital signs after the 28-day period. Weekly phone call reminders and tablet and patch container inventories indicated compliance with the medication instructions.

Effect of Orally Disintegrating Selegiline (Zydis Selegiline) and Selegline Transdermal System (Emsam) on \[^11^C\]Clorgyline Binding in the Brain
--------------------------------------------------------------------------------------------------------------------------------------------------

There were no significant differences in *K*~1~ after either Zydis selegiline or Emsam administration ([Table 2](#tbl2){ref-type="table"}). The average values of *λk*~3~ for the 2.5, 5.0, and 10 mg doses of Zydis selegiline and Emsam groups are presented in [Table 2](#tbl2){ref-type="table"}. There was no difference between the baseline *λk*~3~ values for the three groups, or were there differences between the baseline and post treatment values of *λk*~3~ for the 2.5 and 5.0 mg groups. However, the 10-mg group showed a significant reduction of *λk*~*3*~, which corresponded to a 36.9±19.7% inhibition of MAO-A, although the percent reduction varied between subjects (range 11--70%). [Table 2](#tbl2){ref-type="table"} also shows an increasing reduction in *λk*~*3*~ from baseline values as a function of Zydis dose, although only the 10-mg dose reaches statistical significance. MAO-A reduction can be seen in the averaged PET images at baseline and after treatment with 10 mg Zydis selegiline ([Figure 1](#fig1){ref-type="fig"}, top row). The *λk*~3~ reduction with Emsam ranged from 7.5 to 68% with no significant difference between the 10 mg Zydis selegiline and the Emsam group. We also compared percent change in *λk*~3~ for the 12 individual ROIs for the 10-mg group and found a significant region effect (repeated ANOVA in 12 ROI, F=1.2, *p*=0.04) driven by lower inhibition in the cerebellum relative to other regions of interest.

Individual values for the composite *λk*~3~ values at baseline and after treatment for each of the subjects are shown in [Figure 2](#fig2){ref-type="fig"}. There were no significant associations between percent change in *λk*~3~ after Zydis selegiline and subject\'s age, BMI, genotype or weight-adjusted dose of drug. However, for the 10 mg Zydis selegiline group, there was a significant correlation between baseline *λk*~3~ and percent change in *λk*~3~ with higher baseline *λk*~3~ values showing the largest decreases in MAO-A after drug (*R*=0.83; *p*=0.04)

Baseline *λk*~3~\'s differed by 4% for the one subject (\#094530) who participated in both the Zydis selegiline group and the Emsam group 14 months apart. Test/retest reproducibility for *λk*~3~ was 10.9±5.0% from prior human studies ([@bib16]). Thus, our results indicate that percent MAO-A inhibition with the 10-mg Zydis selegiline dose is at least threefold higher than the test/retest variability.

\[^11^C\]Cocaine Binding in Brain
---------------------------------

For three of the subjects in the 10-mg Zydis selegiline group, we measured DAT availability with \[^11^C\]cocaine at baseline and after treatment. The average non-displaceable binding potential (BP~ND~) although lower with Zydis selegiline did not differ significantly from the baseline ([Figure 1](#fig1){ref-type="fig"}, bottom row; [Table 3](#tbl3){ref-type="table"}). There was a significant decrease in the value of *K*~*1*~ after Zydis selegiline in caudate and putamen but the decrease in cerebellum was not significant ([Table 3](#tbl3){ref-type="table"}). A correlation analysis between the % change in DAT and the % change in MAO-A for the three subjects in whom both measures were made was not significant though we note that the sample size was small.

DISCUSSION
==========

There is growing evidence that different formulations and different routes of administration of the same drug molecule can have a profound effect on drug bioavailability, pharmacokinetics, and pharmacodynamics ([@bib38]). We report here the first measurements confirming brain MAO-A inhibition in humans receiving formulations of selegiline, which reduce or bypass first-pass metabolism. We found that 10 mg of Zydis selegiline for 28 days loses its selectivity for MAO-B and significantly inhibits brain MAO-A and that the Emsam patch for 28 days showed \>30% inhibition of MAO-A in two of the three subjects tested.

Our results confirming inhibition of brain MAO-A with high dose Zydis selegiline and with the Emsam patch provide the first direct evidence in the humans that brain MAO-A inhibition may contribute to its pharmacological and therapeutic profile, particularly for depression. They are consistent with those of Clarke *et al* who reported that repeated doses of high-dose Zydis selegiline reduces the urinary excretion of 5-hydroxy-indoleacetic acid, a peripheral marker for MAO-A activity ([@bib7], [@bib8]), and also with preclinical studies with the selegiline transdermal system which showed targeted inhibition of the MAO enzymes in the CNS while limiting MAO-A inhibition in the gut ([@bib28]).

[@bib29] reported that patients with major depressive disorder have an average 34% elevation of brain MAO-A, which may contribute to the monoamine imbalance in depression. We can speculate that brain MAO-A inhibition by formulations of selegiline, which result in brain MAO-A inhibition, may contribute to a rebalancing of brain monoamines. Interestingly, there is a high comorbidity between smoking and depression ([@bib19]). Biologically based self-medication hypotheses have been proposed to account for this observation including nicotine-induced release of norepinephrine and dopamine, which are neurotransmitters mediating arousal and stimulation ([@bib21]; [@bib30]). As tobacco smoke inhibits brain MAO-A by ∼30% ([@bib16]), brain MAO-A inhibition by cigarette smoke may also contribute to a rebalancing of brain monoamines thus alleviating depression symptoms.

Even though the primary pharmacological action of selegiline is MAO-B inhibition, its pharmacology is complex ([@bib12] for review) and other mechanisms including the actions of amphetamine metabolites ([@bib10]), increased DAT expression ([@bib20]), and DAT upregulation ([@bib45]) have also been proposed to account for the antidepressant efficacy of high doses of selegiline ([@bib27]). Significant decreases in amphetamine metabolites with transdermal ([@bib5]) and orally disintegrating formulations of selegiline ([@bib7]) reduce the likelihood that selegiline metabolites play a role in the pharmacological effects of these formulations. Similar to our prior PET study with conventional selegiline (10 mg/day for 1 week; [@bib15]), we did not find significant brain DAT inhibition by 10 mg Zydis selegiline. We note that DAT inhibitor drugs like methylphenidate and modafinil at therapeutic doses inhibit \>50% of DAT ([@bib44]; [@bib42]), whereas the DAT reduction we observed with Zydis selegiline for three subjects was \<15%, which is not statistically significant and is unlikely to contribute to the pharmacological profile of this formulation.

There was a large individual variability in the percent change in \[^11^C\]clorgyline binding (*λk*~3~) within the 10 mg Zydis selegiline and the Emsam groups ([Figure 2](#fig2){ref-type="fig"}). We found no significant associations between the percent change in \[^11^C\]clorgyline binding and subject demographics or with the weight-adjusted dose of Zydis selegiline. However, there was a significant correlation between baseline *λk*~3~ and percent change in *λk*~3~ for the 10 mg Zydis selegiline group, with higher baseline *λk*~3~ values showing the largest decreases in MAO-A after drug. However, the sample size is small and the mechanism(s) underlying this relationship is unclear.

There is a common polymorphism in the promoter region of the MAOA gene that has two common alleles (4-repeat and 3-repeat) that occur in a 60:40 ratio in male humans, which are commonly referred to as high- and low-MAO-A genotypes as defined by their significantly different transcriptional activities ([@bib34]). The identification of this polymorphism led to the hypothesis that MAO-A genotype may serve as a marker of MAO-A gene function and to many studies of the association between high- and low-MAOA genotype and vulnerability to environmental stressors in humans ([@bib9]). We include MAO-A genotype as one of the variables, which characterize our subjects. In a prior study, we found that high- and low-MAO-A genotype does not correlate with \[^11^C\]clorgyline binding in brain in healthy male volunteers ([@bib18]). In this study, we found no association with the percent change in MAO-A activity with the high-dose Zydis selegiline and Emsam groups and brain MAO-A levels as measured with \[^11^C\]clorgyline.

Our study had some limitations that warrant further investigation. This includes the small sample size particularly for the Emsam measures and the DAT measures. In addition, this was an outpatient study. Subjects were contacted weekly to remind them to take the medication as instructed and each subject returned at least 80% of their empty foil wrappers indicating to us that most of the medication was taken. Selegiline plasma measures would have allowed us to assess if plasma levels of selegiline correlated with the level of brain MAO-A blockade and future studies in a larger number of subjects would enable such a correlation to be explored.

In summary, this is the first direct confirmation of brain MAO-A inhibition in humans by high-dose Zydis selegiline and the Emsam selegiline both of which are currently postulated but not verified to inhibit brain MAO-A in addition to MAO-B. This suggests that brain MAO-A inhibition may account for some of the pharmacological and therapeutic effects of high-dose Zydis selegiline and other formulations of selegiline, which avoid first pass metabolism, including reports of antidepressant activity.
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![Composite PET images of MAO-A (*λk*~3~, top row) and of DAT (BP~ND,~ bottom row) at baseline and after 10 mg of Zydis selegiline administration.](npp2014214f1){#fig1}

![Composite global values of *λk*~3~ for each individual subject at baseline and after a 28-day Zydis selegiline treatment for the 2.5 (upper left), 5.0 (upper right), and 10 mg (lower left) groups. Composite global values for the three Emsam-treated subjects are also shown.](npp2014214f2){#fig2}

###### Demographic Characteristics of Study Participants

                   **Zydis selegiline (2.5 mg)**   **Zydis selegiline (5.0 mg)**   **Zydis selegiline (10 mg)**   **Emsam (6 mg)**
  --------------- ------------------------------- ------------------------------- ------------------------------ ------------------
  *N*                            6                               6                              6                        3
  Age (years)                  27±5                            29±7                            26±5                     32±2
  BMI (kg/m^2^)              24.8±2.0                        25.6±2.9                        27.8±2.5                 26.3±2.0
  Genotype                    4Hi/2Lo                         3Hi/3Lo                        3Hi/3Lo                  2Hi/1Lo

Abbreviations: Hi, high-MAOA genotype; Lo, low-MAOA genotype.

###### Average Model Terms for \[^11^C\]Clorgyline Binding at Baseline and After Treatment with Different Doses of Zydis Selegiline and the Single Dose of Emsam

                     ***K*~1~**   **% Change**   ***P* value**   ***λk*~3~**   **% Change**   ***P* value**
  ------------------ ------------ -------------- --------------- ------------- -------------- ---------------
  *Zydis (2.5 mg)*                                                                            
   Baseline          0.39±0.04                                   0.30±0.02                     
   Drug              0.43±0.06    9.3±14.3       0.16            0.29±0.04     2.1±13.5       0.3
                                                                                               
  *Zydis (5.0 mg)*                                                                            
   Baseline          0.40±0.16                                   0.32±0.04                     
   Drug              0.40±0.07    2.8±18.3       0.8             0.29±0.04     7.4±16.4       0.13
                                                                                               
  *Zydis (10 mg)*                                                                             
   Baseline          0.40±0.05                                   0.32±0.04                     
   Drug              0.37±0.03    −5.1±14.2      0.4             0.19±0.05     36.9±19.7      0.007
                                                                                               
  *Emsam 6 mg)*                                                                               
   Baseline          0.37±0.08                                   0.34±0.04                     
   Drug              0.34±0.08    −4.7±23.4      0.7             0.22±0.09     33.2±28.9      0.10

###### Average Model Terms for \[^11^C\]Cocaine Binding at Baseline and after Zydis Selegiline

  **Region**    **Baseline**   **Zydis selegiline**   ***P* value**
  ------------- -------------- ---------------------- ---------------
  *K*~1~                                              
   Caudate      0.47±0.07      0.40±0.08              0.01
   Putamen      0.53±0.07      0.43±0.06              0.005
   Cerebellum   0.47±0.10      0.37±0.03              0.16
                                                       
  *BP*~*ND*~                                          
   Caudate      0.75±0.18      0.63±0.25              0.2
   Putamen      0.90±0.15      0.83±0.21              0.2
